AZCERT, Inc. is an independent non-profit research and education organization that supports CredibleMeds, an educational program to improve therapeutic outcomes and reduce adverse events caused by drug interactions and drugs that cause heart arrhythmias.
Dr. Woosley earned a Ph.D. in Pharmacology from the University of Louisville (1967) and an M.D. degree from the University of Miami (1971).Dr. Woosley completed Post-doctoral training at the University of Louisville in Pharmacology and at Vanderbilt University in Clinical Pharmacology.
Following graduate school, he served as the first scientist employed by Meyer Laboratories (now GSK, Inc.). After returning to study medicine, he graduated from the University of Miami School of Medicine and then specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University.He remained on the faculty and rose to the rank of Professor of Medicine and Pharmacology.
From 1988 to 2001, he was Chairman of the Department of Pharmacology at Georgetown University.In 2001 he assumed the position of Associate Dean for Clinical Research.From 2001 to 2005 he was Vice President for Health Sciences at The University of Arizona.From 2005 to 2012 he was President and CEO of The Critical Path Institute.In 2012, he founded the not-for-profit AZCERT and serves as President and Chairman of the Board of Directors.He has served on many national advisory committees for the NIH, Veterans Administration, the US Pharmacopeial Convention, the Cardiorenal Advisory Committee of the Food and Drug Administration, the Institute of Medicine (National Academy of Sciences) and chairman of the Joint Advisory Committee on Cardiovascular Drugs for the American Heart Association and the American College of Cardiology.He has served as ad hoc consultant for numerous FDA advisory committees, a Special Consultant for the FDA, and a member of the Director's Advisory Committee on Clinical Research for the NIH's National Center for Research Resources.Dr. Woosley's research has investigated the basic and clinical pharmacology of antiarrhythmic drugs and he is considered an international authority on the drug treatment of arrhythmias.
He has demonstrated the importance of active drug metabolites, stereoisomerism and pharmacogenetic differences in drug metabolism as factors influencing the pharmacologic and clinical response to antiarrhythmic drugs, beta adrenergic antagonists, antimalarials and antihistamines such as terfenadine.
His research has identified the mechanisms responsible for the greater risk of drug-induced arrhythmias in women.
His research has been reported in over 300 publications including 185 original articles, 50 book chapters and 60 invited reviews.
In March of 1990, he received the Rawls-Palmer Award for his contributions to medicine by the American Society of Clinical Pharmacology and Therapeutics.
In 2001, he received the Henry Gold Award from the Society.
He was selected by practicing physicians to be listed in The Best Doctors in America from 1994-2000.
Senator Robert F. Bennett will serve as Chairman of the Board of Directors and Raymond L. Woosley, MD PhD will serve as Chairman of the newly created Board of Scientific Advisors.
Dr. Woosley is among the giants of medicine and clinical pharmacology in America.
He was the Chairman of the Department of Pharmacology and Associate Dean for Clinical Research at Georgetown University Medical Center and Vice-President and Dean of the College of Medicine at the University of Arizona.Founder of the Critical Path Institute (C-Path), Dr. Woosley is widely known and widely published in the field of Clinical Pharmacology and Cardiology.Dr. Woosley said, "The inefficient way we recruit patients for clinical trials and the time it takes to bring drugs to market is unacceptable and unsustainable.
Dr. Kamauu, Senator Bennett, and Raymond L. Woosley, MD PhD, Chairman of the Anolinx™ Board of Scientific Advisors, will also be available for individual interviews.
Dr. Woosley, age 72, was appointed to the ARCA Board of Directors in July 2013.Dr. Woosley is currently the President Emeritus, of the Critical Path Institute (C-Path), a non-profit, public-private partnership with the Federal Food and Drug Administration, of which he was a founder in November 2004, and where he served as President, Chief Executive Officer and Chairman of the Board from 2005 to 2011.Since 2012, Dr. Woosley has also been the Director of CredibleMeds Worldwide, an independent, nonprofit research and education organization.Since 2001, Dr. Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center (UAHSC), and, since 2012, Professor Emeritus, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean of the College of Medicine from 2001 to 2002.From 1988 to 2001, Dr. Woosley was a professor of medicine at the Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994.Dr. Woosley earned his Ph.D. in Pharmacology from the University of Louisville and his M.D. from the University of Miami.
Dr. Woosley’s research has been published in over 265 peer-reviewed publications and 50 book chapters.
Dr. Woosley is an appropriate member of the Company’s Board of Directors, given his expertise and experience in cardiovascular clinical pharmacology, anti-arrhythmic therapeutics, pharmacogenetic drug development and therapeutic regulatory approval.
Raymond Woosley, MD, PhDPresident Emeritus; Former Chairman of the Board
Raymond Woosley, MD, PhDPresident Emeritus; Former Chairman of the BoardPrior to founding Critical Path Institute in 2005, Dr. Raymond Woosley was Vice President for the University of Arizona (UA) Health Sciences Center and Dean of the UA College of Medicine.He also served as Associate Dean of Clinical Research and Chair of the Department of Pharmacology at Georgetown University School of Medicine.Dr. Woosley was a professor at Vanderbilt University Medical School and the first US scientist for GlaxoSmithKline's initial US operations.Dr. Woosley earned his doctorate in Pharmacology from the University of Louisville and his medical degree from the University of Miami.He completed post-doctoral training in pharmacology, internal medicine and clinical pharmacology.
Dr. Woosley's research has been published in over 265 peer-reviewed publications and 50 book chapters.
He is a member of the National Academy of Science's Institute of Medicine's Drug Forum.
Long Realty's Greg Hansen-who spoke to both associations following a presentation by Dr. Raymond Woosley, vice president for health services at the University of Arizona and the university's primary contact for the project-said he has been a member of the associations since 1986, "and I have never seen us take this kind of a leadership role in county economics.Frankly, I think it's about gol' darn time we did."Hansen said he was "somewhat persuasive" when he introduced the ideas that each of the associations should commit $50,000 per year over the five-year funding period.When he heard Woosley's presentation, he said, "I did get excited, I did get jazzed about it."
He said when he heard that other groups or individuals were giving significant amounts of money, he thought the TAR/MLS should be included in that group.This project, he said, compares to when IBM came to Tucson in the late 1970s/early 1980s and when Raytheon came here in the 1990s.
Thank You for Downloading!
1. Download ZoomInfo Grow
2. Run Installation Wizard
3. Check your inbox to Sign in to ZoomInfo Grow